Gibson Lanier Promoted to MCC’s Partnership
January 4, 2021
Meunier Carlin & Curfman LLC (“MCC”) announces the promotion of Dr. Gibson Lanier to its partnership effective January 1, 2021.
Dr. Lanier, a patent attorney with a PhD in immunology and microbiology from Emory University, joined the firm in 2017 from Smith, Gambrell & Russell’s intellectual property practice.
Dr. Lanier advises and prosecutes patents for clients in the biotech and life sciences industries in relation to vaccines, immunological therapies, DNA and protein therapeutics, antibodies, stem cells, immunological screens, biomarkers, transgenic animals, gene therapy, molecular and cellular biological screening assays, diagnostic assays, diagnostic sensors, and peptide/protein therapy. His chemical and pharmaceutical experience includes protecting innovations in pesticides, polymers, plastics, composites, and controlled release vehicles.
“Gibson strategically guides his clients on protecting their biotechnology innovations through patents and managing their patent portfolios, and he has significant research experience in immunological therapies,” said managing partner, Meredith Struby. “His background and promotion come at a critical time for intellectual property related to eliminating the risk of COVID-19 and other infectious diseases. Our clients will benefit from his knowledge and qualifications.”
In addition to his legal practice, Dr. Lanier is heavily involved with both legal and industry groups. He currently sits as a board member for the Georgia Intellectual Property Alliance (GIPA). He also serves on the Public Policy Task Force Committee and the Public Policy Advisory Committee for the Association of University Technology Managers (AUTM). Dr. Lanier previously served as the President and Chair of the Intellectual Property Section of the Atlanta Bar.